HIV Infection:
Clinical Basics
Introduction
Almost 20 years into the epidemic, HIV disease has unquestionably moved out of the
domain of the generalist, and become the nearly exclusive province of the HIV specialist.
The latter are generally, although not always, infectious disease specialists. In spite of
this, military primary care physicians, including GMOs, will provide some care to patients
with established HIV infection. Perhaps more importantly, primary care providers will
serve as the initial (and often only) point of contact with the health care system for
infected individuals in the process of seroconverting.
Seroconversion
Detection of patients in the process of seroconverting (i.e. with acute HIV
illness) is woefully inadequate in all settings, military and civilian; however, it is a
potentially very valuable contribution to the care of these individuals when it occurs. Up
to two-thirds of patients newly infected with HIV will have manifestations of acute
infection, generally referred to as seroconverting illness. Oftentimes this takes the form
of an infectious mono-like illness or "flu." Common symptoms include fever, sore
throat, a maculopapular rash, generalized lymphadenopathy, fatigue, malaise, myalgias,
oral ulcerations, and less commonly an aseptic meningitis. Occasionally, more impressive
manifestations such as thrush, shingles, or even full-blown opportunistic infections may
occur; although these are certainly the exception rather than the rule. While the first
group of symptoms is admittedly nonspecific, any combination of them should suggest the
possibility of HIV seroconversion. This is particularly true if symptoms last for a week
or longer, as illness associated with acute HIV infection generally lasts from one to
several weeks. Current thought is that detection of illness at this stage followed by
aggressive treatment will likely, favorably alter the course of the disease, by lowering
the viral "setpoint" that develops over the first 6 months or so of infection.
As already mentioned, detection of infection at this early stage is highly desirable.
Unfortunately, the majority of the time serology for HIV will still be negative during
this period, and so testing with a surrogate is important. Historically, testing has been
done by checking a p24 antigen and this has now been largely supplanted by an HIV viral
load evaluation. The latter is a highly sensitive and specific test, as viremia is
generally very high during acute infection. If one of these tests cannot be obtained (i.e.
deployment), it is important to check HIV serology shortly after the acute infection,
along with a viral load if possible. A patient found to be seroconverting should be
discussed urgently with an infectious disease specialist, and if possible referred
acutely.
Infection
after Seroconverting
Illness
Although disease may progress unchecked in a subset of patients (perhaps 10
percent) after HIV infection, the large majority of individuals will enjoy a period of
"latent" infection. During this time they will generally be free of symptoms
related to the disease, even though the virus continues to replicate at an astounding
rate, and slowly chops away at the immune system. On average, a loss of about 50
100 CD4+ lymphocytes will occur annually, in the absence of therapy. Particularly since
the advent of the protease inhibitors in 1995, the standard of care is to treat
individuals aggressively in early and middle stages of disease, in the hope of delaying or
preventing progression to advanced disease. This has clearly been successful, with AIDS
deaths down 47 percent in 1997 alone.
Therapy of HIV disease has changed dramatically over the last several years, and will
continue to do so for the foreseeable future. As of late 1998, there are 13
antiretrovirals on the market, with another 3 pending approval. Use of these drugs in
appropriate combinations and sequences is critically important in achieving and sustaining
a good response, and once again should always be done in conjunction with an HIV
specialist.
As the disease progresses to somewhat more advanced stage, a variety of clinical
manifestations may occur. As these often begin to appear when the CD4+ count drops below
350 or 300, they may been seen with some regularity in patients who remain on active duty.
Some of these conditions include generalized lymphadenopathy, zoster (shingles), thrush,
oral hairy leukoplakia, oral ulcers, and recurrent herpetic infections. While none of
these conditions are AIDS-defining or grounds for a medical board by themselves, they are
an indicator of disease progression. By the time a patient meets criteria for a diagnosis
of AIDS (including a CD4+ count of < 200), a medical board should be initiated.
Known or Suspected HIV Exposure
An area of some controversy has been how best to address the individual with
definite or possible exposure to HIV. Examples can include a health care provider who
sustains a needle stick injury with a sharp from an HIV+ patient or an individual who
presents after a sexual exposure to an infected or possibly infected partner. Without
going into excessive detail, it may be safely stated that an individual who sustains a
moderate or high-risk exposure in the health care setting should be emergently counseled
and offered antiretroviral treatment. This should ideally be discussed with an HIV
specialist or at least a general internist, but if this is not possible, strong
consideration should be given to beginning a 3-drug combination (e.g. AZT, 3TC, and a
protease inhibitor such as Indinavir or Nelfinavir). Ideally, this should be done within 2
- 3 hours of the exposure. The decision to give medications after a sexual exposure is
more problematic, and should be handled on a case-by-case basis. Prophylactic medication
should certainly not be given, unless the contact is known to be HIV+.
Web Resources
Revised by CDR James C. Pile, MC, USNR, Infectious Disease
Department, National Naval Medical Center, Bethesda, MD (1999).
|
Preface
· Administrative Section
· Clinical Section
The
General Medical Officer Manual , NAVMEDPUB 5134, January 1, 2000
Bureau
of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C.,
20372-5300
This
web version of The General Medical Officer Manual, NAVMEDPUB 5134 is provided by
The Brookside Associates
Medical Education Division. It contains original contents from the
official US Navy version, but has been reformatted for web access and
includes advertising and links that were not present in the original version.
This web version has not been approved by the Department of the Navy or the
Department of Defense. The presence of any advertising on these pages does not
constitute an endorsement of that product or service by either the Department of
Defense or the Brookside Associates. The Brookside Associates is a private
organization, not affiliated with the United States Department of Defense. All
material in this version is unclassified. This formatting © 2006
Medical Education Division,
Brookside Associates, Ltd.
All rights reserved.
Home
·
Textbooks and Manuals
·
Videos
·
Lectures
·
Distance Learning
·
Training
·
Operational Safety
·
Search
This website is dedicated to the development and dissemination of medical information that may be useful to those who practice Operational Medicine. This website is privately-held and not connected to any governmental agency. The views expressed here are those of the authors, and unless otherwise noted, do not necessarily reflect the views of
the Brookside Associates, Ltd., any governmental or private organizations. All writings, discussions, and publications on this website are unclassified.
© 2006 Medical Education Division, Brookside Associates, Ltd. All rights reserved
Other Brookside Products
Contact Us
|
|